George Yaghmour

Associate Professor of Clinical Medicine

Medical Director, Allogenic Bone Transplant

Image of George Yaghmour
Is this your profile? Click to edit

Overview

George Yaghmour, MD, is an Associate Professor of Clinical Medicine in the Jane Anne Nohl Division of Hematology and Medical Director of the Norris Blood Allogeneic Stem Cell & Bone Marrow Transplant Program at the Keck School of Medicine of USC. Dr. Yaghmour specializes in leukemia, lymphoma, multiple myeloma, bone marrow failure syndromes, Mast cell, other rare hematologic disorders (PNH, HLH), and allogeneic stem cell transplantation at USC Norris Comprehensive Cancer Center. A graduate of the University of Aleppo, he completed his internal medicine residency at Henry Ford Hospital/Wayne State University and a fellowship in hematology and medical oncology at the University of Tennessee Health Sciences Center/West Cancer Center. Board certified in internal medicine, hematology, and medical oncology, he leads nationally recognized transplant and cellular therapy programs, directs clinical research in novel immunotherapies and rare blood disorders, and has authored more than 100 peer-reviewed publications. Deeply committed to mentorship, community service, and patient advocacy, Dr. Yaghmour is an award-winning fundraiser and national leader supporting blood cancer research and care.

Awards

  • Blood cancer United, USC: National all STAR visionary of the year, 2025
  • Leukemia Lymphoma Scociety/USC: Greater Los Angeles Team Member of the Year, LLS, 2024
  • LLS/USC: Advocacy Mission Award, LLS, 2023
  • Keck school of Medicine: Nominated for Faculty Award (inaugural), 2023
  • USC: Visionary of the Year, LLS, 2023
  • Los Angeles Magazine, California Magazine: as “Best in California” by Doctor Magazine, 2021
     – 2024
  • Keck school of medicine USC: Keck Medicine Professionalism Award, 2018
  • Los Angeles Magazine: Top Doctors in Southern CA Rising Stars, 2017
  • Tennessee Oncology Practice Society: Outstanding Fellow Award, 2015
  • Asheville Hematologic Malignancies Symposium: Scholarship Award, 2015
  • VAMC Memphis: Star Team Award, 2014
  • Wayne State University, Henry Ford Hospital: Recognized and Ranked Top 5% Internal Medicine Residents, 2013
  • Henry Ford Hospital: Outstanding Patient Satisfaction/ Care, 2012
  • Aleppo University School of Medicine: Top 1% Graduate Award, 2008

Publications

  • Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. Blood Adv. 2026 09 08; 10(17):5821-5827.. View in PubMed
  • Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2026 Jun 27.. View in PubMed
  • Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026 Jun 02.. View in PubMed
  • Primary Extramedullary Acute Promyelocytic Leukemia Presenting as Cauda Equina Syndrome: A Rare Case Report and Diagnostic Challenge. Clin Case Rep. 2026 Jun; 14(6):e72767.. View in PubMed
  • Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2026 Aug; 26(8):562-573.e1.. View in PubMed
  • Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 Apr 23; 147(17):2011-2017.. View in PubMed
  • Case Report: Complete remission of refractory Langerhans cell sarcoma following CLAG-M chemotherapy and allogeneic hematopoietic stem cell transplant. Front Oncol. 2026; 16:1714214.. View in PubMed
  • Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives. Oncol Res. 2026; 34(3):4.. View in PubMed
  • CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. Blood Adv. 2026 Jan 13; 10(1):276-288.. View in PubMed
  • Acute Myeloid Leukemia With a Non-Canonical FLT3 V491L Mutation: A Case Report With Ex Vivo FLT3 Inhibitors Sensitivity Testing. J Med Cases. 2026 Jan; 17(1):14-20.. View in PubMed